Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
- 1 March 2012
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 11 (5) , 865-870
Abstract
Active avoidance by tumor cells from attack and elimination by immune cells is an emerging cancer hallmark that is achieved primarily through decreasing the levels of major histocompatibility complex class I (MHC-I) at the cancer cells’ surface. Deficiencies in MHC-I antigen-restricted immunosurveillance may be intertwined with an altered, Warburg-like cancer cell-intrinsic metabolism, another emerging hallmark of cancer that involves a switch from mitochondrial respiration to glycolysis to efficiently support large-scale biosynthetic programs that are required for active cell proliferation. We recently envisioned that intervention strategies aimed at reversing the bioenergetic signature of cancer cells (e.g., the antidiabetic biguanide metformin) should correct oncogene (e.g., HER2)-driven MHC-I defects, thus preventing immune escape of oncogene transformants. First, we explored how metformin treatment impacted mitochondrial biogenesis in cultured breast cancer cells overexpressing the membrane tyrosine kinase receptor HER2, the best-characterized downregulator of MHC-I. Metformin exposure was found to dose-dependently increase the expression levels of cytochrome c oxidase I and mitochondrial succinate dehydrogenase, which are encoded by mitochondrial and nuclear DNA, respectively. Second, we explored whether metformin-enhanced mitochondrial biogenesis might significantly alter the MHC-I status in breast carcinoma cells. MHC-I expression, as assessed by flow cytometry using an anti-HLA-ABC monoclonal antibody, was fully restored (up to ~25-fold upregulation) in MHC-I-negative HER2 gene-amplified carcinoma cells. These findings may help delineate a previously unrecognized mechanism through which metformin (and metformin-like drugs) may enable a cancer patient’s own immune system to mount an efficient anti-metastasis response that can prevent or delay disease recurrence. Restored antigenicity and immunogenicity of tumor cells may represent a previously unrecognized primary mode of action underlying the cancer-preventive effects of metformin.Keywords
This publication has 48 references indexed in Scilit:
- Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma PatientsClinical Cancer Research, 2010
- Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulationGynecologic Oncology, 2008
- Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapyImmunogenetics, 2008
- Molecular mechanisms of MHC class I abnormalities and APM components in human tumorsCancer Immunology, Immunotherapy, 2008
- HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccinationCancer Immunology, Immunotherapy, 2006
- Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosisInternational Journal of Cancer, 2005
- Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brainLaboratory Investigation, 2005
- MHC class I antigens, immune surveillance, and tumor immune escapeJournal of Cellular Physiology, 2003
- MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients.International Journal of Cancer, 2001
- Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblastsEuropean Journal of Immunology, 1998